HEMATOLOGY

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.

Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).

New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.

Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Carfilzomib (Kyprolis) in combination with dexamethasone, was recently granted a priority review designation by the FDA for patients who have relapsed multiple myeloma, following prior treatment with at least one therapy.

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).

Aziz Nazha, MD, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Srdan Verstovsek, MD, PhD, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.

AbbVie has submitted a supplemental new drug application for its BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia (CLL) who are over the age of 65.

Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, discusses new drugs on the horizon for the treatment of patients with chronic lymphocytic leukemia (CLL).

Ixazomib (MLN9708), an oral proteasome inhibitor, was recently granted a priority review designation by the FDA, in combination with lenalidomide and dexamethasone for the treatment of patients who have relapsed and/or refractory multiple myeloma.

Daratumumab was recently assigned a priority review designation by the FDA as a treatment for patients who have multiple myeloma.

US Veterans, including former Air Force personnel who participated in Operation Ranch Hand, have a 2.4-fold increased risk of multiple myeloma’s precursor state, MGUS,

A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.

The therapeutic palette for Hodgkin Lymphoma is growing, along with improvements in survival and cure rates.

Genetic testing may improve treatment for multiple myeloma by helping oncologists identify patients at risk for developing more aggressive disease.

The development of novel targeted drugs, such as brentuximab vedotin (Adcentris), against discrete cell surface proteins, such as CD30, has awakened a new way of thinking about targeted cancer biology